comparemela.com

Latest Breaking News On - Murano trial - Page 1 : comparemela.com

Venetoclax and Rituximab Combination Maintains Survival Benefit in Relapsed/Refractory CLL

Patients with relapsed/refractory chronic lymphocytic leukemia achieved sustained progression-free survival and overall survival benefit after treatment with fixed-duration venetoclax plus rituximab vs bendamustine plus rituximab, according to data from the phase 3 MURANO trial.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.